FNCHQ · Finch Therapeutics Group, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“due to the consideration of certain qualitative factors, including the Company's recurring losses from operations incurred since inception, the expectation of continuing operating losses for the foreseeable future, and uncertainty around its ability to successfully realize the full value of its intellectual property estate and other assets, the Company has concluded that there is substantial doubt regarding the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2024
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| $0 | $107K | $861K | $18.53M | $7.72M | |
| $0 | $7.2M | $52.86M | $57.28M | $33.14M | |
| $19.69M | $26.91M | $36.19M | $21.24M | $14.01M | |
| $183K | $1.52M | $5.51M | $2.3M | $790K | |
| -$185K | $3.82M | $2.42M | $0 | — | |
| $19.5M | $83.97M | $116.45M | $78.52M | $47.16M | |
| -$19.5M | -$83.86M | -$115.59M | -$59.99M | -$39.44M | |
| — | -78374.77% | -13425.44% | -323.68% | -510.9% | |
| -$19.32M | -$82.34M | -$110.09M | -$57.68M | -$38.65M | |
| $5.34M | $5.65M | $947K | $1.83M | $95K | |
| -$14.17M | -$78.22M | -$114.65M | -$58.16M | -$39.34M | |
| $0 | -$3.46M | $0 | $0 | $0 | |
| -$14.17M | -$74.75M | -$114.65M | -$58.16M | -$39.34M | |
| — | -69863.55% | -13315.45% | -313.84% | -509.66% | |
| USD/shares | -$8.49 | -$46.59 | -$72.12 | -$44.40 | — |
| USD/shares | -$8.49 | -$46.59 | -$72.12 | -$44.40 | — |
| shares | — | 1.6M | 1.59M | 1.31M | 271.5K |
| shares | — | 1.6M | 1.59M | 1.31M | 271.5K |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2024-06-30 | USD 2,094,000 | 10-Q filed 2024-08-13 |
| Noncurrent operating lease liabilities | 2024-06-30 | USD 26,895,000 | 10-Q filed 2024-08-13 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Collaboration Revenue | $861,000 | $18,532,000 | $7,376,000 |
| Royalties Revenue from Related Party | — | — | $343,000 |